ExCellThera is a clinical stage biotechnology company that is focused on developing robust and cost effective ways of growing blood stem cells for therapeutic use. Our first product is expected to deliver superior therapeutic benefits for acute myeloid leukemia (AML), a type of cancer that is characterized by the rapid growth of abnormal white blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age.
ExCellThera is also interested in pursuing partnerships for the use of its technologies in other blood stem cell applications, including gene therapy.
ExCellThera has developed a unique way of producing high-quality blood stem cells in large quantities. ExCellThera’s technology will improve the outcome of stem cell transplants in patients by allowing for better-matched donors. You can read more about this on the Canadian Cancer Society site.
ExCellThera’s best-in-class cell culture system combines an innovative bioreactor technology with a novel small molecule, UM171, that targets long-term hematopoietic stem cells (HSCs). When combined, these technologies expand blood progenitors (CD34+ cells) more than 50-fold in 12-days and enable the significant expansion of primitive HSCs, potentially allowing the robust long-term reconstitution of the blood forming system from small HSC samples. The ExCellThera technology represents a unique combination of manufacturing and biological solutions to the long-standing problem of blood stem cell growth. The result is a robust and economic ex-vivo expansion of umbilical cord blood (UCB)-derived long-term HSCs and CD34+ progenitors for bone marrow transplants. The UM171 compound, owned by ExCellThera, also enhances gene transfer to HSC, thus opening unprecedented avenues for exploiting these cells to cure genetic diseases such as thalassemia or sickle cell anemia.